醋酸阿比特龙联合泼尼松龙±恩扎卢胺用于转移性前列腺癌起始雄激素剥夺治疗的患者:STAMPEDE平台方案两项随机3期试验的最终结果
STAMPEDE平台方案在117个中心开展两项开放标签随机3期试验,评估起始雄激素剥夺治疗时加用阿比特龙或阿比特龙联合恩扎卢胺的长期生存。阿比特龙组中位总生存76.6个月优于标准治疗组45.7个月(HR 0.62),阿比特龙联合恩扎卢胺组中位总生存73.1个月优于标准治疗组51.8个月(HR 0.65),两试验疗效无差异,但联合组3-5级毒性最高(68% vs 45%)。
要点
- 阿比特龙联合泼尼松龙加用于起始雄激素剥夺治疗,中位总生存76.6个月 vs 标准治疗45.7个月(HR 0.62)。
- 阿比特龙联合泼尼松龙加恩扎卢胺组中位总生存73.1个月 vs 标准治疗51.8个月(HR 0.65)。
- 两项试验疗效无差异(交互作用HR 1.05),但联合恩扎卢胺组3-5级毒性最高(68% vs 45%)。
核心结论
- 恩扎卢胺与阿比特龙不应联合用于起始长期雄激素剥夺治疗的前列腺癌患者。
- 阿比特龙加用于雄激素剥夺治疗带来的具有临床意义的生存改善维持超过7年。
研究设计与样本
- STAMPEDE平台方案的两项开放标签、随机、对照3期试验,无重叠对照,在英国和瑞士117个中心开展。
- 阿比特龙试验纳入1003例患者,随机分至标准治疗(n=502)或标准治疗加阿比特龙(n=501),随机时间2011年11月15日至2014年1月17日。
- 阿比特龙联合恩扎卢胺试验纳入916例患者,随机分至标准治疗(n=454)或标准治疗加阿比特龙和恩扎卢胺(n=462),随机时间2014年7月29日至2016年3月31日。
- 入组标准为转移性组织学确诊前列腺腺癌、WHO体能状态0-2、血液学及肝肾功能充分,无年龄限制。
- 主要终点为意向性治疗人群的总生存,安全性在所有开始治疗的患者中评估,采用固定效应Meta分析比较两试验生存差异。
主要发现
- 阿比特龙试验中位随访96个月(IQR 86-107),阿比特龙组中位总生存76.6个月(95% CI 67.8-86.9)vs 标准治疗组45.7个月(41.6-52.0),HR 0.62(95% CI 0.53-0.73),p<0.0001。
- 阿比特龙联合恩扎卢胺试验中位随访72个月(61-74),联合组中位总生存73.1个月(61.9-81.3)vs 标准治疗组51.8个月(45.3-59.0),HR 0.65(0.55-0.77),p<0.0001。
- 两项试验间治疗效应无差异(交互作用HR 1.05 [0.83-1.32],pinteraction=0.71),试验间异质性无差异(I2 p=0.70)。
- 治疗前5年内,阿比特龙加标准治疗组3-5级毒性271例(54%,498例中)vs 标准治疗组192例(38%,502例中)。
- 阿比特龙联合恩扎卢胺加标准治疗组3-5级毒性302例(68%,445例中)vs 标准治疗组204例(45%,454例中);心脏原因是不良事件所致死亡最常见原因,联合组5例(1%,其中2例归因于治疗),阿比特龙试验标准治疗组1例(<1%)。
关键数值与推荐
- 标准治疗为雄激素剥夺治疗;多西他赛75 mg/m2静脉给药6个周期,自2015年12月17日起允许口服泼尼松龙10 mg每日一次。
- 阿比特龙试验干预为口服醋酸阿比特龙1000 mg加泼尼松龙5 mg。
- 阿比特龙联合恩扎卢胺试验干预为醋酸阿比特龙加泼尼松龙再加口服恩扎卢胺160 mg每日一次。
临床怎么用
- 作者结论认为恩扎卢胺与阿比特龙不应联合用于起始长期雄激素剥夺治疗的前列腺癌患者。
- 阿比特龙加用于雄激素剥夺治疗带来的具有临床意义的生存改善维持超过7年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed to evaluate long-term outcomes and test whether combining enzalutamide with abiraterone and androgen deprivation therapy improves survival. METHODS: We analysed two open-label, randomised, controlled, phase 3 trials of the STAMPEDE platform protocol, with no overlapping controls, conducted at 117 sites in the UK and Switzerland. Eligible patients (no age restriction) had metastatic, histologically-confirmed prostate adenocarcinoma; a WHO performance status of 0-2; and adequate haematological, renal, and liver function. Patients were randomly assigned (1:1) using a computerised algorithm and a minimisation technique to either standard of care (androgen deprivation therapy; docetaxel 75 mg/m2 intravenously for six cycles with prednisolone 10 mg orally once per day allowed from Dec 17, 2015) or standard of care plus abiraterone acetate 1000 mg and prednisolone 5 mg (in the abiraterone trial) orally or abiraterone acetate and prednisolone plus enzalutamide 160 mg orally once a day (in the abiraterone and enzalutamide trial). Patients were stratified by centre, age, WHO performance status, type of androgen deprivation therapy, use of aspirin or non-steroidal anti-inflammatory drugs, pelvic nodal status, planned radiotherapy, and planned docetaxel use. The primary outcome was overall survival assessed in the intention-to-treat population. Safety was assessed in all patients who started treatment. A fixed-effects meta-analysis of individual patient data was used to compare differences in survival between the two trials. STAMPEDE is registered with ClinicalTrials.gov (NCT00268476) and ISRCTN (ISRCTN78818544). FINDINGS: Between Nov 15, 2011, and Jan 17, 2014, 1003 patients were randomly assigned to standard of care (n=502) or standard of care plus abiraterone (n=501) in the abiraterone trial. Between July 29, 2014, and March 31, 2016, 916 patients were randomly assigned to standard of care (n=454) or standard of care plus abiraterone and enzalutamide (n=462) in the abiraterone and enzalutamide trial. Median follow-up was 96 months (IQR 86-107) in the abiraterone trial and 72 months (61-74) in the abiraterone and enzalutamide trial. In the abiraterone trial, median overall survival was 76·6 months (95% CI 67·8-86·9) in the abiraterone group versus 45·7 months (41·6-52·0) in the standard of care group (hazard ratio [HR] 0·62 [95% CI 0·53-0·73]; p<0·0001). In the abiraterone and enzalutamide trial, median overall survival was 73·1 months (61·9-81·3) in the abiraterone and enzalutamide group versus 51·8 months (45·3-59·0) in the standard of care group (HR 0·65 [0·55-0·77]; p<0·0001). We found no difference in the treatment effect between these two trials (interaction HR 1·05 [0·83-1·32]; pinteraction=0·71) or between-trial heterogeneity (I2 p=0·70). In the first 5 years of treatment, grade 3-5 toxic effects were higher when abiraterone was added to standard of care (271 [54%] of 498 vs 192 [38%] of 502 with standard of care) and the highest toxic effects were seen when abiraterone and enzalutamide were added to standard of care (302 [68%] of 445 vs 204 [45%] of 454 with standard of care). Cardiac causes were the most common cause of death due to adverse events (five [1%] with standard of care plus abiraterone and enzalutamide [two attributed to treatment] and one (<1%) with standard of care in the abiraterone trial). INTERPRETATION: Enzalutamide and abiraterone should not be combined for patients with prostate cancer starting long-term androgen deprivation therapy. Clinically important improvements in survival from addition of abiraterone to androgen deprivation therapy are maintained for longer than 7 years. FUNDING: Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas.
引用
- Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol. 2023. PMID: 37142371. doi:10.1016/S1470-2045(23)00148-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。